ECSP13012667A - Compuestos de triazolopiridina - Google Patents

Compuestos de triazolopiridina

Info

Publication number
ECSP13012667A
ECSP13012667A ECSP13012667A ECSP13012667A EC SP13012667 A ECSP13012667 A EC SP13012667A EC SP13012667 A ECSP13012667 A EC SP13012667A EC SP13012667 A ECSP13012667 A EC SP13012667A
Authority
EC
Ecuador
Prior art keywords
compounds
triazolopiridine
medicines
formula
well
Prior art date
Application number
Other languages
English (en)
Inventor
Alexander Flohr
Jens-Uwe Peters
Luca Gobbi
Zbinden Katrin Groebke
Matthias Koerner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP13012667A publication Critical patent/ECSP13012667A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a compuestos de triazolopiridina de la fórmula (I) (I)en la que R1, R2, R3 y R4 tienen los significados definidos en la descripción y en las reivindicaciones, así como a las sales fisiológicamente aceptables de los mismos. Estos compuestos inhiben la PDE10A y pueden utilizarse como medicamentos.
ECSP13012667 2010-12-07 2013-06-06 Compuestos de triazolopiridina ECSP13012667A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10194014 2010-12-07

Publications (1)

Publication Number Publication Date
ECSP13012667A true ECSP13012667A (es) 2013-08-30

Family

ID=45099086

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012667 ECSP13012667A (es) 2010-12-07 2013-06-06 Compuestos de triazolopiridina

Country Status (31)

Country Link
US (1) US8349824B2 (es)
EP (1) EP2649070B1 (es)
JP (1) JP5932828B2 (es)
KR (1) KR20130128426A (es)
CN (1) CN103237803B (es)
AR (1) AR084152A1 (es)
AU (1) AU2011340685A1 (es)
BR (1) BR112013013912A2 (es)
CA (1) CA2816829C (es)
CL (1) CL2013001591A1 (es)
CO (1) CO6741154A2 (es)
CR (1) CR20130239A (es)
CY (1) CY1115863T1 (es)
DK (1) DK2649070T3 (es)
EA (1) EA022607B1 (es)
EC (1) ECSP13012667A (es)
ES (1) ES2520647T3 (es)
HR (1) HRP20141200T1 (es)
IL (1) IL225969A0 (es)
MA (1) MA35086B1 (es)
MX (1) MX2013006054A (es)
PE (1) PE20140226A1 (es)
PH (1) PH12013500942A1 (es)
PL (1) PL2649070T3 (es)
PT (1) PT2649070E (es)
RS (1) RS53677B1 (es)
SG (1) SG190305A1 (es)
SI (1) SI2649070T1 (es)
UA (1) UA109037C2 (es)
WO (1) WO2012076430A1 (es)
ZA (1) ZA201303811B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9193724B2 (en) 2011-09-22 2015-11-24 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
RU2620379C2 (ru) * 2012-02-09 2017-05-25 Ф.Хоффманн-Ля Рош Аг СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 2-ФЕНИЛ[1,2,4]ТРИАЗОЛО[1,5-а]ПИРИДИНА
BR112015017674A2 (pt) * 2013-01-31 2017-07-11 Hoffmann La Roche compostos rádio marcados
HUE043059T2 (hu) * 2013-02-27 2019-07-29 Mochida Pharm Co Ltd Új pirazolszármazék
JP2016520047A (ja) * 2013-04-30 2016-07-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピラゾールアミドのＰｄ触媒カップリング
US9708314B2 (en) * 2013-05-31 2017-07-18 Nissan Chemical Industries, Ltd. Heterocyclic amide compound
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
WO2016017719A1 (ja) * 2014-07-30 2016-02-04 持田製薬株式会社 ピラゾール誘導体の製造方法
WO2016017711A1 (ja) * 2014-07-30 2016-02-04 持田製薬株式会社 ピラゾール誘導体の製造方法
JP6745594B2 (ja) * 2015-11-26 2020-08-26 持田製薬株式会社 ピラゾール誘導体の塩の結晶
WO2020021024A1 (en) * 2018-07-26 2020-01-30 Phenex Pharmaceuticals Ag Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
US12544364B2 (en) 2020-06-05 2026-02-10 Noema Pharma Ag Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
MX2022015400A (es) 2020-06-05 2023-03-16 Noema Pharma Ag Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del sindrome de tourette.
WO2022162193A1 (en) 2021-01-28 2022-08-04 Noema Pharma Ag Methods for the treatment of childhood-onset fluency disorder
CN117157077A (zh) * 2021-01-28 2023-12-01 诺埃玛制药公司 儿童期发病的流畅性障碍的治疗方法
WO2026068583A1 (en) 2024-09-25 2026-04-02 Noema Pharma Ag Use of phosphodiesterase 10 inhibitor gemlapodect for weight loss

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物

Also Published As

Publication number Publication date
EA022607B1 (ru) 2016-01-29
CA2816829C (en) 2018-12-04
WO2012076430A1 (en) 2012-06-14
JP5932828B2 (ja) 2016-06-08
CA2816829A1 (en) 2012-06-14
CY1115863T1 (el) 2017-01-25
EA201390799A1 (ru) 2013-12-30
CL2013001591A1 (es) 2013-12-27
SI2649070T1 (sl) 2014-12-31
PH12013500942A1 (en) 2017-05-19
PE20140226A1 (es) 2014-03-08
KR20130128426A (ko) 2013-11-26
ZA201303811B (en) 2014-04-30
MA35086B1 (fr) 2014-05-02
CR20130239A (es) 2013-06-27
PT2649070E (pt) 2014-11-21
CO6741154A2 (es) 2013-08-30
US8349824B2 (en) 2013-01-08
CN103237803A (zh) 2013-08-07
MX2013006054A (es) 2013-06-18
SG190305A1 (en) 2013-06-28
ES2520647T3 (es) 2014-11-11
AU2011340685A1 (en) 2013-05-23
BR112013013912A2 (pt) 2016-09-13
EP2649070B1 (en) 2014-09-17
UA109037C2 (uk) 2015-07-10
DK2649070T3 (da) 2014-10-13
JP2013544859A (ja) 2013-12-19
AR084152A1 (es) 2013-04-24
RS53677B1 (sr) 2015-04-30
EP2649070A1 (en) 2013-10-16
CN103237803B (zh) 2016-04-13
HRP20141200T1 (hr) 2015-02-13
IL225969A0 (en) 2013-06-27
PL2649070T3 (pl) 2015-03-31
US20120142665A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
CR20130239A (es) Compuestos de triazolopiridina
ECSP12012174A (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
ECSP13013074A (es) Nuevos derivados de piridina
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
CR20150250A (es) Nuevos derivados de piridina
DOP2011000382A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
CO6620065A2 (es) Compuestos heteroarilo nitrogenados
CR20150204A (es) Nuevos derivados de piridina
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
CO6541606A2 (es) Espiroindolinona- pirrolidinas
MX2019009100A (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
CR20150045A (es) Inhibidores de hepatitis c
UA108711C2 (uk) Сполуки триазолопіридину як інгібітори фосфодіестерази pde10a
CR20140275A (es) Triazolopiridinas sustituidas
CR20150440A (es) Nuevos derivados de piridina
CR20150447A (es) Nuevos derivados de pirazol
CR20140481A (es) Compuestos triazolo como inhibidores de pde10
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
CR20150511A (es) Nuevos derivados de purina
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
UY31000A1 (es) Oxoisoxazoles como inhibidores de lipasas y fosfolipasas
HN2009001330A (es) Compuestos novedosos activos como antagonistas de receptore muscarinico
BR112014019220A8 (pt) Novos derivados de pirrolidina